Lenvatinib in Second Line Endometrial Carcinoma

Inclusion Criteria: * Female subjects age ≥18 years at the time of informed consent * World Health Organization (WHO) Performance Status of 0 or 1 * Patients with histologically confirmed endometrial cancer including serous-papillary and clear cell histologies. Uterine carcinosarcomas are allowed. * Radiographic evidence of disease progression according to RECIST 1.1 after 1 prior systemic, platinum-based chemotherapy regimen for metastatic or primary unresectable endometrial carcinoma for which no surgical or radiotherapy treatment options exist. * Patients with disease progression following platinum-based chemotherapy administered as either adjuvant or neoadjuvant treatment are also eligible. * Patients may have received prior radiotherapy and / or adjuvant chemotherapy for early high-risk disease * Patients may not have received prior treatment with anthracyclines * Blood samples available for retrospective central assessment of Ang-2 level * Patients may have had prior therapy providing the following conditions are met: * Surgery and radiation therapy: wash-out period of 14 days and subjects must have recovered adequately from any toxicity and/or complications from radiotherapy and major surgery prior to starting therapy. * Systemic anti-tumor therapy or any investigational agent: wash-out period of 21 days (or 5 x half-life) * Recovery from any toxic effects of prior therapy to ≤ Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.) except alopecia * Adequate contraceptive measures * Signed written informed consent Exclusion Criteria: * Inadequate hematologic, renal and hepatic functions * Abnormal cardiac function